ID: h-d799fa0468
Hypothesis
Combination RGS6 restoration plus D2-pathway modulation
Combine subthreshold RGS6 rescue with D2-pathway modulation to test whether benefit requires convergent normalization of autoreceptor-Gi/o signaling.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Combine subthreshold RGS6 rescue with D2-pathway modulation to test whether benefit requires convergent normalization of autoreceptor-Gi/o signaling. This remains secondary to monotherapy studies and should not be prioritized until RGS6-alone efficacy and the relevant signaling mechanism are established.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["RGS6 Restoration<br/>Regulator of G Protein Signaling 6"]
B["D2 Autoreceptor<br/>Pathway Modulation"]
C["G Protein Signaling<br/>Normalized"]
D["Dopamine Neurotransmission<br/>Homeostasis Restored"]
E["Combined RGS6 + D2<br/>Therapeutic Approach"]
F["RGS6 as Central<br/>Modulation Target"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix3 supports2 contradicts
Supports
If RGS6 acts mainly by constraining D2-Gi/o signaling, combination perturbation could help determine whether that pathway is necessary for any rescue signal.
Supports
RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.
Contradicts
This hypothesis inherits the weaknesses of both RGS6 overexpression and D2 agonism, without independent supporting evidence for synergy in established PD pathology.
Contradicts
The proposed pSer129-centered mechanism is unstable because Ser129 phosphorylation can be downstream of aggregation and may even reduce seeded toxicity in some contexts.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — RGS6
No curated PDB or AlphaFold mapping for RGS6 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for RGS6 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for RGS6.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↗
Rising
7d Momentum
▲ 2.0%
Volatility
Medium
0.0304
Events (7d)
3
Price History
▲35.4%💾 Resource Usage
LLM Tokens
11,782
$0.0353
Total Cost
$0.0353
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF subthreshold RGS6 restoration via AAV9‑RGS6 in adult rats is combined with a low‑dose D2 antagonist (eticlopride), THEN we will see a synergistic reduction in dopaminergic neuron loss in the substa | Stereological counts of TH‑positive neurons in the SNpc will be at least 40 % higher in the combination group compared with the AAV‑RGS6 alone group and at leas | — no observation — | pending | 0.50 |
| IF subthreshold AAV-mediated RGS6 overexpression combined with chronic low-dose D2 agonist (quinpirole) is administered to MPTP‑lesioned C57BL/6 mice, THEN we will observe a significantly greater impr | Rotarod latency in the combination group will be at least 30 % longer than in the vehicle group, exceeding the improvement seen with either AAV‑RGS6 or quinpiro | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF subthreshold AAV-mediated RGS6 overexpression combined with chronic low-dose D2 agonist (quinpirole) is administered to MPTP‑lesioned C57BL/6 mice, THEN we will observe a significantly greater improvement in motor coordination (rotarod latency) compared to either monotherapy alone within 6 weeks
Predicted outcome: Rotarod latency in the combination group will be at least 30 % longer than in the vehicle group, exceeding the improvement seen with either AAV‑RGS6 o
Falsification: The combination group shows no statistically significant difference in rotarod performance compared with the best monotherapy group (p > 0.05) or the improvement is <20 % above vehicle, indicating lac
pendingconf 50%
IF subthreshold RGS6 restoration via AAV9‑RGS6 in adult rats is combined with a low‑dose D2 antagonist (eticlopride), THEN we will see a synergistic reduction in dopaminergic neuron loss in the substantia nigra pars compacta relative to monotherapy or vehicle within 8 weeks after viral delivery.
Predicted outcome: Stereological counts of TH‑positive neurons in the SNpc will be at least 40 % higher in the combination group compared with the AAV‑RGS6 alone group a
Falsification: The number of surviving TH‑positive neurons in the combination group does not differ significantly from either monotherapy group (p > 0.05) or is <20 % above the vehicle control, demonstrating no adde
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.